Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management
Safety was equally impressive. ENV-294 was well tolerated
Board approves five-year appointment, subject to shareholder nod through postal ballot
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
Subscribe To Our Newsletter & Stay Updated
